Methods and compositions for protecting against neurotoxic agents

Abstract

Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and/or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent. Additionally provided are methods for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for preserving or improving motor coordination in the subject.

Description

field of invention [0001] Certain aspects relate generally to methods of preventing or reducing neurotoxicity when exposed to a neurotoxic agent, comprising administering an electrokinetic altered aqueous fluid as provided herein, and preferably, wherein preventing in a subject exposed to a neurotoxin Or lower loss of motor coordination. Particular aspects relate to preventing or reducing neurotoxin-mediated neuronal apoptosis, and / or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons. Certain aspects relate generally to methods of preserving or improving motor coordination in a subject suffering from a neurodegenerative disorder or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein. Cross references to related patent applications [0002] This patent application claims U.S. Patent Application No. 12 / 771,476, filed April 30, 2010 and entitled "COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODE GE...

AI Technical Summary

Problems solved by technology

Dopamine agonists and monoamine oxidase type B inhibitors have shown that efficacy is inversely related to the incidence and severity of side effects, while studies of other treatment options, including coenzyme Q10, tocopherol (vitamin E), amantadine, and beta-blockers stanchants) trials either failed to show a beneficial effect or did not have sufficient data for a thorough assessment of risks and benefits

Images